Systematic review, meta-analysis and economic modelling of ...
Systematic review, meta-analysis and economic modelling of ... Systematic review, meta-analysis and economic modelling of ...
Appendix 7Lambda (λ), £ Prob NoT Prob 10% Prob 99th Prob Hi SensProb 10-hourTrop27,000 0 0.0177 0.0453 0.4258 0.511228,000 0 0.0162 0.0431 0.4158 0.524929,000 0 0.0151 0.0407 0.4070 0.537230,000 0 0.0144 0.0377 0.3944 0.553531,000 0 0.0135 0.0357 0.3848 0.566032,000 0 0.0131 0.0342 0.3750 0.577733,000 0 0.0128 0.0329 0.3659 0.588434,000 0 0.0127 0.0312 0.3562 0.599935,000 0 0.0122 0.0299 0.3480 0.609936,000 0 0.0113 0.0287 0.3409 0.619137,000 0 0.0103 0.0283 0.3319 0.629538,000 0 0.0093 0.0269 0.3252 0.638639,000 0 0.0089 0.0259 0.3192 0.646040,000 0 0.0089 0.0253 0.3130 0.652841,000 0 0.0085 0.0241 0.3067 0.660742,000 0 0.0083 0.0235 0.2999 0.668343,000 0 0.0078 0.0233 0.2915 0.677444,000 0 0.0075 0.0229 0.2847 0.684945,000 0 0.0072 0.0226 0.2790 0.691246,000 0 0.0070 0.0222 0.2738 0.697047,000 0 0.0068 0.0216 0.2685 0.703148,000 0 0.0066 0.0206 0.2639 0.708949,000 0 0.0064 0.0197 0.2580 0.715950,000 0 0.0060 0.0194 0.2527 0.7219Prob 10%, probability that using standard troponin at presentation with a 10% coefficient of variation threshold is costeffective;Prob 10-hour trop, probability that using standard troponin at 10 hours is cost-effective; Prob 99th, probabilitythat using standard troponin at presentation with a 99th percentile threshold is cost-effective; Prob Hi Sens, probabilitythat using high-sensitivity troponin at presentation is cost-effective; Prob NoT, probability that no testing or treatment iscost-effective.168NIHR Journals Library
DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 1Probability of cost-effectiveness in twice-daily ward scenarioLambda (λ), £ Prob NoT Prob 10% Prob 99th Prob Hi SensProb 10-hourTrop0 1 0 0 0 01000 1 0 0 0 02000 1 0 0 0 03000 0.1089 0.6946 0.1965 0 04000 0.0003 0.5894 0.3816 0.0287 05000 0 0.4845 0.4236 0.0919 06000 0 0.4093 0.4173 0.1734 07000 0 0.3519 0.3998 0.2483 08000 0 0.3060 0.3778 0.3160 0.00029000 0 0.2667 0.3548 0.3783 0.000210,000 0 0.2366 0.3349 0.4276 0.000911,000 0 0.2111 0.3117 0.4753 0.001912,000 0 0.1927 0.2928 0.5100 0.004513,000 0 0.1748 0.2768 0.5403 0.008114,000 0 0.1612 0.2585 0.5665 0.013815,000 0 0.1486 0.2453 0.5864 0.019716,000 0 0.1370 0.2345 0.6019 0.026617,000 0 0.1271 0.2238 0.6131 0.036018,000 0 0.1178 0.2129 0.6234 0.045919,000 0 0.1091 0.2037 0.6300 0.057220,000 0 0.1030 0.1932 0.6352 0.068621,000 0 0.0968 0.1820 0.6388 0.082422,000 0 0.0905 0.1734 0.6429 0.093223,000 0 0.0844 0.1648 0.6437 0.107124,000 0 0.0792 0.1552 0.6422 0.123425,000 0 0.0751 0.1464 0.6414 0.137126,000 0 0.0707 0.1386 0.6398 0.150927,000 0 0.0671 0.1321 0.6378 0.163028,000 0 0.0641 0.1273 0.6357 0.172929,000 0 0.0597 0.1208 0.6343 0.185230,000 0 0.0569 0.1169 0.6295 0.196731,000 0 0.0534 0.1124 0.6248 0.209432,000 0 0.0505 0.1082 0.6207 0.220633,000 0 0.0476 0.1051 0.6145 0.232834,000 0 0.0455 0.1015 0.6100 0.2430© Queen’s Printer and Controller of HMSO 2013. This work was produced by Goodacre et al. under the terms of a commissioning contract issued by the Secretary of Statefor Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journalsprovided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton SciencePark, Southampton SO16 7NS, UK.169
- Page 138 and 139: ConclusionsSuggested research prior
- Page 141 and 142: DOI: 10.3310/hta17010 Health Techno
- Page 143 and 144: DOI: 10.3310/hta17010 Health Techno
- Page 145 and 146: DOI: 10.3310/hta17010 Health Techno
- Page 147 and 148: DOI: 10.3310/hta17010 Health Techno
- Page 149 and 150: DOI: 10.3310/hta17010 Health Techno
- Page 151: DOI: 10.3310/hta17010 Health Techno
- Page 154 and 155: Appendix 144. heart-type fatty acid
- Page 156 and 157: Appendix 1135. interleukin 33.mp. (
- Page 158 and 159: Appendix 147. 37 and 45 (529)48. li
- Page 161: DOI: 10.3310/hta17010 Health Techno
- Page 164 and 165: Appendix 313. Fernandez Portales JG
- Page 166 and 167: Appendix 346. Luscher MS, Ravkilde
- Page 168 and 169: Appendix 316. Rao SV, Ohman EM, Gra
- Page 171 and 172: DOI: 10.3310/hta17010 Health Techno
- Page 173 and 174: DOI: 10.3310/hta17010 Health Techno
- Page 175 and 176: DOI: 10.3310/hta17010 Health Techno
- Page 177 and 178: DOI: 10.3310/hta17010 Health Techno
- Page 179 and 180: DOI: 10.3310/hta17010 Health Techno
- Page 181 and 182: DOI: 10.3310/hta17010 Health Techno
- Page 183: DOI: 10.3310/hta17010 Health Techno
- Page 187: DOI: 10.3310/hta17010 Health Techno
- Page 191 and 192: DOI: 10.3310/hta17010 Health Techno
- Page 193 and 194: DOI: 10.3310/hta17010 Health Techno
- Page 195: DOI: 10.3310/hta17010 Health Techno
- Page 198 and 199: Appendix 9Clinical diagnosis of NST
- Page 200 and 201: Appendix 9respectively. Exercise EC
- Page 202 and 203: Appendix 93. Two reviewers will mak
- Page 204 and 205: Appendix 9The methodology used in t
- Page 206 and 207: Appendix 9ES (Information Resources
- Page 208: Appendix 923. Westwood ME, Whiting
DOI: 10.3310/hta17010 Health Technology Assessment 2013 Vol. 17 No. 1Probability <strong>of</strong> cost-effectiveness in twice-daily ward scenarioLambda (λ), £ Prob NoT Prob 10% Prob 99th Prob Hi SensProb 10-hourTrop0 1 0 0 0 01000 1 0 0 0 02000 1 0 0 0 03000 0.1089 0.6946 0.1965 0 04000 0.0003 0.5894 0.3816 0.0287 05000 0 0.4845 0.4236 0.0919 06000 0 0.4093 0.4173 0.1734 07000 0 0.3519 0.3998 0.2483 08000 0 0.3060 0.3778 0.3160 0.00029000 0 0.2667 0.3548 0.3783 0.000210,000 0 0.2366 0.3349 0.4276 0.000911,000 0 0.2111 0.3117 0.4753 0.001912,000 0 0.1927 0.2928 0.5100 0.004513,000 0 0.1748 0.2768 0.5403 0.008114,000 0 0.1612 0.2585 0.5665 0.013815,000 0 0.1486 0.2453 0.5864 0.019716,000 0 0.1370 0.2345 0.6019 0.026617,000 0 0.1271 0.2238 0.6131 0.036018,000 0 0.1178 0.2129 0.6234 0.045919,000 0 0.1091 0.2037 0.6300 0.057220,000 0 0.1030 0.1932 0.6352 0.068621,000 0 0.0968 0.1820 0.6388 0.082422,000 0 0.0905 0.1734 0.6429 0.093223,000 0 0.0844 0.1648 0.6437 0.107124,000 0 0.0792 0.1552 0.6422 0.123425,000 0 0.0751 0.1464 0.6414 0.137126,000 0 0.0707 0.1386 0.6398 0.150927,000 0 0.0671 0.1321 0.6378 0.163028,000 0 0.0641 0.1273 0.6357 0.172929,000 0 0.0597 0.1208 0.6343 0.185230,000 0 0.0569 0.1169 0.6295 0.196731,000 0 0.0534 0.1124 0.6248 0.209432,000 0 0.0505 0.1082 0.6207 0.220633,000 0 0.0476 0.1051 0.6145 0.232834,000 0 0.0455 0.1015 0.6100 0.2430© Queen’s Printer <strong>and</strong> Controller <strong>of</strong> HMSO 2013. This work was produced by Goodacre et al. under the terms <strong>of</strong> a commissioning contract issued by the Secretary <strong>of</strong> Statefor Health. This issue may be freely reproduced for the purposes <strong>of</strong> private research <strong>and</strong> study <strong>and</strong> extracts (or indeed, the full report) may be included in pr<strong>of</strong>essional journalsprovided that suitable acknowledgement is made <strong>and</strong> the reproduction is not associated with any form <strong>of</strong> advertising. Applications for commercial reproduction should beaddressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials <strong>and</strong> Studies Coordinating Centre, Alpha House, University <strong>of</strong> Southampton SciencePark, Southampton SO16 7NS, UK.169
Change language